ライフサイエンスコーパス: varicella-zoster virus

1 ese is also activated by the closely related varicella zoster virus.

2 ew mutations or recombination with wild-type Varicella zoster virus.

3 2, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus.

4 losely related to herpes simplex viruses and varicella-zoster virus.

5 G synthesis, and elevated antibody titers to varicella-zoster virus.

6 d, for example, in relation to pertussis and varicella-zoster virus.

7 ation were detected in OPV, mumps virus, and varicella-zoster virus.

8 uses herpes simplex virus type 1 (HSV-1) and varicella-zoster virus.

9 known as breakthrough disease, if exposed to varicella-zoster virus.

10 erpesviruses herpes simplex virus type 1 and varicella-zoster virus.

11 nuated varicella vaccine virus and wild-type varicella-zoster virus.

12 gens herpes simplex virus type 1 (HSV-1) and varicella-zoster virus.

13 1), P. jirovecii pneumonia (1.77; .42-7.47), varicella-zoster virus (1.51; .71-3.22), as well as over

14 -Barr virus, 3%; herpes simplex virus 1, 3%; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex

15 For herpes simplex virus, varicella zoster virus and cytomegalovirus, these advanc

16 RN, PCR-positive for herpes simplex virus or varicella zoster virus and evaluated between January 200

17 genes of both herpes simplex virus (HSV) and varicella zoster virus and functions, in part, by coupli

18 beyond CMV to other herpes viruses, such as varicella zoster virus and possibly Epstein-Barr virus.

19 ld decrease external boosting of immunity to varicella zoster virus and thereby increase incidence of

20 cropsy of two monkeys inoculated with simian varicella-zoster virus and euthanized 117 days later.

21 ia in adults includes common agents, such as varicella-zoster virus and influenza virus, as well as r

22 ate changes in the molecular epidemiology of varicella-zoster virus and the effect of immunization wi

23 ty of herpes simplex virus, cytomegalovirus, varicella zoster virus, and Epstein-Barr virus in our po

24 Herpes simplex virus, varicella zoster virus, and pseudorabies virus are neuro

25 2, human herpesvirus 6, human parechovirus, varicella-zoster virus, and Cryptococcus neoformans/Cryp

26 antigens (vaccinia, measles, mumps, rubella, varicella-zoster virus, and Epstein-Barr virus) and nonr

27 Findings from skin biopsy, viral culture for varicella-zoster virus, and skin prick test to common fo

28 Varicella-zoster virus antigen was found in 45 of 70 GCA

29 Varicella-zoster virus antigen was frequently found in p

30 e whether herpes zoster antigen (also called varicella-zoster virus antigen) was detectable in tempor

31 gical boosting, through which reexposures to varicella-zoster virus are thought to reduce the individ

32 nstrate that childhood infections, including varicella zoster virus, are associated with an increased

33 h HLA-B27-associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778] pg/mL) uv

34 for other infections (herpes simplex virus, varicella zoster virus, bacterial and fungal infections)

35 itis (AU), owing to either herpes simplex or varicella zoster virus, by using the Standardization of

36 clonal antibodies against a major antigen of varicella-zoster virus called gE.

37 se encephalitis virus, herpes simplex virus, varicella zoster virus, cytomegalovirus, dengue virus an

38 (HSV) and other alphaherpesviruses, such as varicella-zoster virus, depend upon the capacity to navi

39 ES by the corresponding region from ORF61 of varicella-zoster virus did not rescue ND10 fusion.

40 (as determined by testing lesions swabs for varicella zoster virus DNA by polymerase chain reaction)

41 ence of confirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from

42 Varicella zoster virus DNA was detected 2 months after t

43 bstrates for gene suicide therapy or as anti-varicella zoster virus drugs.

44 th HSE (p.Leu297Val) and 1 in a patient with varicella-zoster virus encephalitis (p.Leu199Phe).

45 the phenotypic spectrum of TLR3 mutations to varicella-zoster virus encephalitis and support the role

46 Varicella zoster virus encodes a thymidine kinase respon

47 Varicella zoster virus encodes an immediate-early (IE) p

48 The ORF29 gene of varicella-zoster virus encodes a single-stranded DNA bin

49 deficiency virus (HIV)-herpes simplex virus, varicella zoster virus, Epstein-Barr virus (EBV), and cy

50 rpes zoster is a common late complication of varicella-zoster virus exposure and can be further compl

51 hus, a 30-h delay after death did not affect varicella-zoster virus expression in latently infected g

52 Studies of varicella-zoster virus gene expression during latency re

53 The varicella-zoster virus geometric mean titer (GMT) and ge

54 were randomized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant Sy

55 ve (at months 0, 1, 3) three doses of 50 mug varicella-zoster virus glycoprotein E (gE) adjuvanted wi

56 An adjuvanted varicella-zoster virus glycoprotein E (gE) subunit vacci

57 ubjects received 3 doses of HZ/su (50 microg varicella-zoster virus glycoprotein E [gE] combined with

58 g older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adju

59 zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with su

60 equences of wild-type and vaccine strains of varicella-zoster virus have been published and listed in

61 gnificant members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epste

62 transfected cells, whereas expression of the varicella-zoster virus ICP22 homolog, ORF63, does not.

63 rveillance, combined with information from a Varicella Zoster Virus Identification Program, which use

64 highly dependent on the host cell, we tested varicella zoster virus-infected cell lysates and clinica

65 cation) were associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95

66 contact dermatitis, infectious folliculitis, varicella zoster virus infection, fixed drug eruption, a

67 processes, including ubiquitin clearance and Varicella Zoster Virus infection.

68 or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more we

69 erties that may favor reactivation of latent varicella-zoster virus infection.

70 nd increased susceptibility to bacterial and varicella zoster virus infections.

71 s related to herpes simplex virus type 1 and varicella-zoster virus, infects a broad host range of ma

72 While varicella-zoster virus is also insensitive to interferon

73 regulate infection of host cells.IMPORTANCE Varicella-zoster virus is an important human pathogen, w

74 Because features of varicella-zoster virus latency are similar in primate an

75 Similarly, in a varicella zoster virus lytic infection, HCF-1, Set1, and

76 The varicella-zoster virus major transactivator, IE62, can a

77 The varicella-zoster virus major transactivator, IE62, conta

78 One patient with varicella zoster virus meningitis and acute GVHD had iC9

79 Available varicella-zoster virus models can be classified in 3 mai

80 es (parechovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyss

81 = 60), followed by tuberculosis (n = 8) and varicella zoster virus (n = 7).

82 e fills a notable gap in our knowledge about varicella zoster virus neuronal transportation.

83 -coinfected children and were independent of varicella-zoster virus or herpes-simplex virus 1 coinfec

84 stituents at C6 exhibit remarkable anti-VZV (varicella-zoster virus) potency and selectivity, and ana

85 Herpes Simplex Virus types 1 and 2 and Varicella-zoster virus produce neurotropic infections su

86 Because there is no good animal model of varicella zoster virus reactivation from latency, this e

87 genes, Treponema pallidium, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and He

88 Among the 131 live births to varicella-zoster virus-seronegative women, there was no

89 in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to va

90 1, CTLA-4, and TIM-3, whereas <2% of CMV- or varicella-zoster virus-specific CD4(+) T cells expressed

91 the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA)

92 e-based site-directed mutagenesis studies of varicella zoster virus thymidine kinase (VZVTK).

93 lives ranging from an estimated 50 years for varicella-zoster virus to more than 200 years for other

94 ng heat-inactivated or replication-defective varicella-zoster virus to prevent HZ in immunocompromise

95 Varicella-zoster virus vaccination to prevent herpes zos

96 The continued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-z

97 The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in

98 s HSV1 and HSV2 (also termed HHV1 and HHV2), varicella zoster virus (VZV or HHV3), EBV (HHV4), cytome

99 tients showed a decreased ability to control varicella zoster virus (VZV) and Epstein-Barr virus (EBV

100 Varicella zoster virus (VZV) and the two herpes simplex

101 Varicella zoster virus (VZV) antibody titers (measured b

102 Varicella zoster virus (VZV) antigen was found in all of

103 Vasculopathies caused by varicella zoster virus (VZV) are indicative of a product

104 CMV and varicella zoster virus (VZV) are significant causes of m

105 response biomarkers measuring antibodies to varicella zoster virus (VZV) by glycoprotein-based enzym

106 lex virus types 1 (HSV-1) and 2 (HSV-2), and varicella zoster virus (VZV) by weekly polymerase chain

107 se of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a

108 , or no history of zoster (group 3) revealed varicella zoster virus (VZV) DNA in saliva samples from

109 rs who were immunized with Zostavax revealed varicella zoster virus (VZV) DNA in swabs of skin inocul

110 Herpesvirions and varicella zoster virus (VZV) DNA were recently reported

111 Varicella zoster virus (VZV) establishes latency in dors

112 Varicella zoster virus (VZV) establishes lifelong persis

113 as an alternative to sampling of rashes for varicella zoster virus (VZV) genotyping and further char

114 s positive for herpes simplex virus (HSV) or varicella zoster virus (VZV) in 79% to 100% of cases of

115 Clinical reports observe the reactivation of varicella zoster virus (VZV) in people who have recovere

116 Reactivation of the varicella zoster virus (VZV) increases during aging.

117 Varicella zoster virus (VZV) infections are a relevant c

118 virus (CMV), herpes simplex virus (HSV), and varicella zoster virus (VZV) infections were monitored i

119 Varicella zoster virus (VZV) is a neurotropic alphaherpe

120 Varicella Zoster Virus (VZV) is the causative agent of v

121 Varicella zoster virus (VZV) is the etiological agent of

122 Varicella zoster virus (VZV) reactivation results in zos

123 An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being de

124 zoster (HZ) cases may play a larger role in varicella zoster virus (VZV) transmission.

125 Varicella zoster virus (VZV) typically causes chickenpox

126 ne responses to a high-titer live attenuated varicella zoster virus (VZV) vaccine (zoster vaccine), w

127 Since the introduction of live attenuated varicella zoster virus (VZV) vaccine in 1995 there has b

128 s, granulomatous aortitis, and intracerebral varicella zoster virus (VZV) vasculopathy.

129 portion of HZ cases caused by vaccine-strain varicella zoster virus (VZV), assessed the positive pred

130 c primers to detect DNA from JC virus (JCV), varicella zoster virus (VZV), cytomegalovirus (CMV), Eps

131 on childhood disease, chicken pox, caused by varicella zoster virus (VZV), over an 11-y period.

132 erpesviruses, herpes simplex virus (HSV) and varicella zoster virus (VZV), results in the rapid accum

133 immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereaft

134 Boost of varicella zoster virus (VZV)-specific cellular immunity

135 We investigated the relationship between varicella zoster virus (VZV)-specific memory CD4(+) T ce

136 virus type 1 (HSV-1) and type 2 (HSV-2) and varicella zoster virus (VZV)-was determined in autonomic

137 ses with age, which leads to reactivation of varicella zoster virus (VZV).

138 1 and 2 and the sequence-divergent pathogen varicella zoster virus (VZV).

139 Varicella-zoster virus (VZV) activates the phosphatidyli

140 SV functioned as a monopartite NLS, while in varicella-zoster virus (VZV) activity required an adjace

141 are the main architectural contrasts between varicella-zoster virus (VZV) and herpes simplex virus (H

142 d the Us9 homologs from two human pathogens, varicella-zoster virus (VZV) and herpes simplex virus ty

143 Intraocular varicella-zoster virus (VZV) and HSV type 1 (HSV-1) infe

144 Although the homologs from varicella-zoster virus (VZV) and human cytomegalovirus (

145 simplex virus type 1 (HSV-1) is conserved in varicella-zoster virus (VZV) and pseudorabies virus (PRV

146 ype 1 (EHV-1), pseudorabies virus (PRV), and varicella-zoster virus (VZV) and their subsequent functi

147 Simian varicella virus (SVV) and varicella-zoster virus (VZV) are closely related alphahe

148 gument proteins encoded by ORF11 and ORF9 of varicella-zoster virus (VZV) are conserved among all alp

149 mmunity and protects against reactivation of varicella-zoster virus (VZV) as HZ.

150 Infection of human neurons in vitro with varicella-zoster virus (VZV) at a low multiplicity of in

151 y, IDE has been proposed as the receptor for varicella-zoster virus (VZV) attachment.

152 The attenuation of varicella-zoster virus (VZV) by Takahashi in 1974 was a

153 Serum was tested for antibodies against varicella-zoster virus (VZV) by use of the previously va

154 Varicella-zoster virus (VZV) causes chicken pox and shin

155 Varicella-zoster virus (VZV) causes chickenpox and react

156 highly infectious, human-restricted pathogen varicella-zoster virus (VZV) causes chickenpox and shing

157 ating VZV from clinical specimens.IMPORTANCE Varicella-zoster virus (VZV) causes chickenpox and shing

158 Varicella-zoster virus (VZV) causes chickenpox upon prim

159 Varicella-zoster virus (VZV) causes varicella and establ

160 Varicella-zoster virus (VZV) causes varicella, establish

161 Varicella-zoster virus (VZV) characteristically forms mu

162 y throughout the study and were analyzed for varicella-zoster virus (VZV) DNA by use of both qualitat

163 Wild-type varicella-zoster virus (VZV) DNA was identified in all 3

164 15, pain was scored and saliva examined for varicella-zoster virus (VZV) DNA.

165 The attenuated Oka vaccine (V-Oka) strain of varicella-zoster virus (VZV) effectively reduces disease

166 Herein we describe an episode of focal varicella-zoster virus (VZV) encephalitis in a healthy y

167 The open reading frame 10 (ORF10) of varicella-zoster virus (VZV) encodes a tegument protein

168 Varicella-zoster virus (VZV) establishes a lifelong late

169 The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a lifelong late

170 Varicella-zoster virus (VZV) establishes latency in huma

171 ts had similar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measu

172 When grown in cultured cells, varicella-zoster virus (VZV) forms many aberrant light p

173 Information about varicella-zoster virus (VZV) gB is limited, but homology

174 d c-Jun are important for transactivation of varicella-zoster virus (VZV) genes.

175 Varicella-zoster virus (VZV) glycoprotein E (gE) is esse

176 Varicella-zoster virus (VZV) glycoprotein E (gE) is requ

177 tive target for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV) has infected over 90% of pe

178 Mechanisms of neuronal infection by varicella-zoster virus (VZV) have been challenging to st

179 umoral and cell-mediated immune responses to varicella-zoster virus (VZV) have been evaluated after 1

180 (EBV) EB2, herpes simplex virus (HSV) ICP27, varicella-zoster virus (VZV) IE4/ORF4, and cytomegalovir

181 The varicella-zoster virus (VZV) IE62 protein is the major t

182 Varicella-zoster virus (VZV) immediate-early 63 protein

183 ction by enveloped, but not cell-associated, varicella-zoster virus (VZV) in a dose-dependent manner

184 ects immediate-early protein IE63 encoded by varicella-zoster virus (VZV) in the cytoplasm of product

185 Productive infection of varicella-zoster virus (VZV) in vitro is restricted almo

186 Varicella-zoster virus (VZV) induces apoptosis in human

187 Previous studies have demonstrated that varicella-zoster virus (VZV) infection activates ERK1/2,

188 Varicella-zoster virus (VZV) infection causes varicella,

189 Primary varicella-zoster virus (VZV) infection in humans produce

190 Varicella-zoster virus (VZV) infection is usually mild i

191 Transcriptional changes following varicella-zoster virus (VZV) infection of cultured human

192 acaques (RMs) recapitulates the hallmarks of varicella-zoster virus (VZV) infection of humans, includ

193 Varicella-zoster virus (VZV) infection provides a valuab

194 he lytic, latent, and reactivating phases of varicella-zoster virus (VZV) infection were recapitulate

195 extensively studied the role of autophagy in varicella-zoster virus (VZV) infection, and have observe

196 Varicella-zoster virus (VZV) infections increasingly are

197 Varicella-zoster virus (VZV) is a common pathogen that c

198 Varicella-zoster virus (VZV) is a highly contagious agen

199 Varicella-zoster virus (VZV) is a highly neurotropic vir

200 Varicella-zoster virus (VZV) is a human alpha-herpesviru

201 Varicella-zoster virus (VZV) is a human alphaherpesvirus

202 Varicella-zoster virus (VZV) is a human alphaherpesvirus

203 Varicella-zoster virus (VZV) is a human neurotropic alph

204 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV) is a major viral trans-acti

205 Varicella-zoster virus (VZV) is a member of the Herpesvi

206 Varicella-zoster virus (VZV) is a neurotropic alphaherpe

207 Varicella-zoster virus (VZV) is a ubiquitous pathogen th

208 Varicella-zoster virus (VZV) is a ubiquitous, highly cel

209 Varicella-zoster virus (VZV) is an alphaherpesvirus that

210 Varicella-zoster virus (VZV) is an alphaherpesvirus that

211 Varicella-zoster virus (VZV) is an alphaherpesvirus that

212 Varicella-zoster virus (VZV) is an alphaherpesvirus that

213 Varicella-zoster virus (VZV) is an extremely cell-associ

214 Varicella-zoster virus (VZV) is highly cell associated w

215 mary infection, latency, and reactivation by varicella-zoster virus (VZV) is incompletely understood.

216 Varicella-zoster virus (VZV) is renowned for its low tit

217 Varicella-zoster virus (VZV) is renowned for its very lo

218 Varicella-zoster virus (VZV) is the alphaherpesvirus tha

219 Varicella-zoster virus (VZV) is the causative agent of b

220 Varicella-zoster virus (VZV) is the causative agent of c

221 Varicella-zoster virus (VZV) is the etiological agent of

222 The varicella-zoster virus (VZV) major transactivator, IE62,

223 We report a case of AIDS presenting as varicella-zoster virus (VZV) meningomyeloradiculitis ass

224 To efficiently generate varicella-zoster virus (VZV) mutants, we inserted a bact

225 f herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) on 695 consecutive cutaneou

226 Varicella-zoster virus (VZV) open reading frame (ORF) 63

227 Varicella-zoster virus (VZV) open reading frame (ORF) 63

228 Varicella-zoster virus (VZV) open reading frame 10 (ORF1

229 Based on comparative genome analyses, varicella-zoster virus (VZV) open reading frame 23 (ORF2

230 The varicella-zoster virus (VZV) open reading frame 54 (ORF5

231 Varicella-zoster virus (VZV) open reading frame 61 (ORF6

232 Three loci in varicella-zoster virus (VZV) open reading frame 62 (ORF6

233 Varicella-zoster virus (VZV) open reading frame 63 (ORF6

234 Varicella-zoster virus (VZV) open reading frame 63 (ORF6

235 Varicella-zoster virus (VZV) open reading frame 66 (ORF6

236 We show here that the varicella-zoster virus (VZV) open reading frame 66 (ORF6

237 The gene cluster composed of varicella-zoster virus (VZV) open reading frame 9 (ORF9)

238 f transcripts corresponding to all 68 unique varicella-zoster virus (VZV) open reading frames (ORFs)

239 Varicella-zoster virus (VZV) ORF29 encodes the viral sin

240 The varicella-zoster virus (VZV) ORF61 protein is necessary

241 The varicella-zoster virus (VZV) ORF62/63 intergenic region

242 The architecture of the varicella-zoster virus (VZV) origin of DNA replication (

243 The varicella-zoster virus (VZV) origin of DNA replication (

244 In this report, we show that ORF61p, the varicella-zoster virus (VZV) ortholog of ICP0, does not

245 ced syncytium formation, a characteristic of varicella-zoster virus (VZV) pathology in skin and senso

246 this minireview is to provide an overview of varicella-zoster virus (VZV) phylogenetics and phylogeog

247 We examined varicella-zoster virus (VZV) polymerase chain reaction (

248 er acyclovir prophylaxis should be given for varicella-zoster virus (VZV) prophylaxis after hematopoi

249 Analyses of varicella-zoster virus (VZV) protein expression during l

250 ORF66p, a virion-associated varicella-zoster virus (VZV) protein, is a member of a c

251 nt is associated with increased incidence of varicella-zoster virus (VZV) reactivation in patients wi

252 IMPORTANCE The neurological damage caused by varicella-zoster virus (VZV) reactivation is commonly ma

253 a total of five major genotypes among the 22 varicella-zoster virus (VZV) strains or isolates for whi

254 Varicella-zoster virus (VZV) T-cell responses by interfe

255 Varicella-zoster virus (VZV) T-cell-mediated immunity (V

256 The varicella-zoster virus (VZV) terminase components (pORF2

257 r herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) to the BD Max system by usi

258 Studies of varicella-zoster virus (VZV) tropism for T cells support

259 Although a varicella-zoster virus (VZV) vaccine has been used for m

260 75 years) immunized with the live-attenuated varicella-zoster virus (VZV) vaccine.

261 of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine.

262 Varicella-zoster virus (VZV) vasculopathy produces strok

263 ish adverse events associated with wild-type varicella-zoster virus (VZV) versus those associated wit

264 Varicella-zoster virus (VZV), a double-stranded DNA alph

265 igated during the entire infectious cycle of varicella-zoster virus (VZV), a human herpesvirus.

266 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV), a major viral trans-activa

267 Primary infection with varicella-zoster virus (VZV), a neurotropic alphaherpesv

268 Regulation of gene transcription in varicella-zoster virus (VZV), a ubiquitous human neurotr

269 1) and pseudorabies virus (PRV) and ORF66 in varicella-zoster virus (VZV), affects several viral and

270 Varicella-zoster virus (VZV), an alphaherpesvirus restri

271 Here we report that varicella-zoster virus (VZV), an alphaherpesvirus that i

272 pear healthy at 2 weeks after infection with varicella-zoster virus (VZV), and the cell culture mediu

273 ovirus, herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), and West Nile virus (WNV).

274 sviruses, herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), confirmed the expression o

275 ults for herpes simplex virus 1/2 (HSV-1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV), or

276 In this study, quantitative PCR detected varicella-zoster virus (VZV), herpes simplex virus 1 (HS

277 Levels of inhibition of varicella-zoster virus (VZV), human cytomegalovirus (HCM

278 Varicella-zoster virus (VZV), in both wild-type and live

279 Varicella-zoster virus (VZV), of the family Alphaherpesv

280 showed cytopathic changes, but HSV-1, unlike varicella-zoster virus (VZV), only rarely infected satel

281 Like varicella-zoster virus (VZV), simian varicella virus (SV

282 cilitate the generation of mutant viruses of varicella-zoster virus (VZV), the agent causing varicell

283 nation was more likely to identify wild-type varicella-zoster virus (VZV), whereas the presence of Ok

284 In varicella-zoster virus (VZV)-infected primary human brai

285 the risk of herpes zoster (HZ), we compared varicella-zoster virus (VZV)-specific and nonspecific T-

286 Varicella-zoster virus (VZV)-specific cell-mediated immu

287 n association with an age-related decline in varicella-zoster virus (VZV)-specific cell-mediated immu

288 udy were to evaluate the association between varicella-zoster virus (VZV)-specific humoral and cell-m

289 To measure varicella-zoster virus (VZV)-specific immune responses u

290 lication that can occur with reactivation of varicella-zoster virus (VZV).

291 rus (CMV), herpes simplex viruses (HSV), and varicella-zoster virus (VZV).

292 rpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV).

293 ly recognized component of the life cycle of varicella-zoster virus (VZV).

294 potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV).

295 itive GCA is associated with TA infection by varicella-zoster virus (VZV).

296 None have yet been reported in varicella-zoster virus (VZV; also known as human herpesv

297 onal and pathogen-specific stimulation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

298 HHV-1 and Varicella-Zoster virus were detected only twice and HHV-

299 ty for CMV, EBV, herpes-simplex virus 1, and varicella-zoster virus were studied in 1079 6-year-old c

300 ncing to identify nosocomial transmission of varicella-zoster virus with fatal outcome.